Improving Universal Pediatric Lipid Screening

Kathleen DeSantes1, Ann Dodge2, Jens Eickhoff3

  • 1Department of Pediatrics, Division of General Pediatrics and Adolescent Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.

Insights

Pediatricians significantly increased universal lipid screening after national guidelines, electronic health record (EHR) modifications, and education. Targeting adolescents aged 12-16 improved screening rates, showing these strategies enhance guideline adherence.

Area of Science:

  • Pediatric Health
  • Preventive Medicine
  • Public Health

Background:

  • Universal lipid screening in children is recommended by national guidelines.
  • Adherence to these guidelines has historically been suboptimal.
  • Identifying effective strategies to improve screening practices is crucial for early detection of dyslipidemia.

Purpose of the Study:

  • To assess the impact of national guidelines, electronic health record (EHR) modifications, and educational initiatives on pediatricians' universal lipid screening practices.
  • To determine the correlation between these interventions and changes in screening prevalence over time.

Main Methods:

  • A retrospective review of electronic health records (EHRs) from an academic general pediatric practice was conducted.
  • The study analyzed lipid screening order placement for 22,374 patients aged 9-21 years between January 2010 and December 2015.
  • Prevalence data were compared with the timing of guideline releases, educational programs, and EHR system changes.

Main Results:

  • Lipid screening order placement increased from 8.9% to 50.0% over the study period (P < .001).
  • Significant increases in screening were observed across all age groups following guideline publications, educational initiatives, and EHR modifications (P < .0001).
  • The composite prevalence of screening, accounting for order placement and completion, reached 46.8%.

Conclusions:

  • Educational initiatives and EHR modifications can substantially improve adherence to universal lipid screening recommendations.
  • Expanding screening targets to include adolescents aged 12-16 years, in addition to recommended age groups, enhanced screening prevalence.
  • These strategies offer a scalable model for implementing other clinical guidelines in pediatric practice.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
338
Lipid Absorption01:24

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
710
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387